IGF2 and gastrointestinal stromal tumor: In addition, IGF1R-targeted therapy of wild-type GIST is under investigation in clinical trials (e.g., NCT01560260), and the heterogeneity of IGF1R and IGF2 expression in the GIST groups may portend differential responses.